Patent · US Active

Ranking system for immunogenic cancer-specific epitopes

US11485784B2 · kind B2 · utility

0Cited by

0References

20Claims

0Family size

Inventors

Pei-Jia Yang · Taipei, TW
Jen-Hao Cheng · Hsinchu, TW
Ying Chen · Taipei, TW
Shu-Jen Chen · Taipei, TW
Hua Chen · Zhejiang, CN

Key dates

Filing date	Mar 31, 2018
Grant date	Nov 1, 2022
Priority date	—
Expiry date	Feb 17, 2040

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

This disclosure relates to systems and methods that identify, predict, and rank immunogenic T-cell epitopes. In particular, this disclosure identifies epitopes that arose from disease-associated mutations, wherein the epitopes are predicted to elicit immune response from T cells. Specifically, this disclosure simultaneously considers peptide-level information, including MHC Class I and II presentation, helper and cytotoxic T cell response and sample-level information, including mutation clonality and MHC allele dosage. In some embodiment, the systems and methods are used for personalized treatment of cancers.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.